Ebola virus infections in nonhuman primates are temporally influenced by Glycoprotein Poly-U editing site populations in the exposure material

Viruses

Volumn 7, Issue 12, 2015, Pages 6739-6754

  Trefry, John C ^a   Wollen, Suzanne E ^a   Nasar, Farooq ^a   Shamblin, Joshua D ^a   Kern, Steven J ^a   Bearss, Jeremy J ^a   Jefferson, Michelle A ^a   Chance, Taylor B ^a   Kugelman, Jeffery R ^a   Ladner, Jason T ^a   Honko, Anna N ^a   Kobs, Dean J ^b   Wending, Morgan Q S ^b   Sabourin, Carol L ^b   Pratt, William D ^a   Palacios, Gustavo F ^a   Pitt, M Louise M ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

Animal model; Ebola virus; Filovirus; Glycoprotein; Kikwit; Nonhuman primate; Pathogenesis; RNA editing; Therapeutic; Vaccine

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN POLY U; UNCLASSIFIED DRUG; ENVELOPE GLYCOPROTEIN, EBOLA VIRUS; POLYURIDYLIC ACID; VIRULENCE FACTOR; VIRUS ENVELOPE PROTEIN;

ARTICLE; AUTOPSY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; GENE EXPRESSION; GENE MUTATION; HEMATOLOGY; HISTOLOGY; KAPLAN MEIER METHOD; NONHUMAN; PATHOGENESIS; PATHOGENICITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EDITING; SEQUENCE ANALYSIS; TELEMETRY; TRANSCRIPTION INITIATION; VACCINATION; ANIMAL; CHEMISTRY; DISEASE MODEL; INTRAMUSCULAR DRUG ADMINISTRATION; MACACA FASCICULARIS; METABOLISM; PATHOLOGY; SURVIVAL ANALYSIS; VIROLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HEMORRHAGIC FEVER, EBOLA; INJECTIONS, INTRAMUSCULAR; MACACA FASCICULARIS; POLY U; SURVIVAL ANALYSIS; VIRAL ENVELOPE PROTEINS; VIRULENCE FACTORS;

EID: 84951098598     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7122969     Document Type: Article

References (55)

1. Sanchez, A.; Trappier, S.G.; Mahy, B.W.; Peters, C.J.; Nichol, S.T. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl. Acad. Sci. USA 1996, 93, 3602-3607. [CrossRef] [PubMed].
2. Volchkov, V.E.; Becker, S.; Volchkova, V.A.; Ternovoj, V.A.; Kotov, A.N.; Netesov, S.V.; Klenk, H.D. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 1995, 214, 421-430. [CrossRef] [PubMed].
3. Volchkov, V.E.; Volchkova, V.A.; Slenczka, W.; Klenk, H.D.; Feldmann, H. Release of viral glycoproteins during Ebola virus infection. Virology 1998, 245, 110-119. [CrossRef] [PubMed].
4. Mohan, G.S.; Li, W.; Ye, L.; Compans, R.W.; Yang, C. Antigenic subversion: A novel mechanism of host immune evasion by Ebola virus. PLoS Pathog. 2012, 8, e1003065. [CrossRef] [PubMed].
5. Kugelman, J.R.; Lee, M.S.; Rossi, C.A.; McCarthy, S.E.; Radoshitzky, S.R.; Dye, J.M.; Hensley, L.E.; Honko, A.; Kuhn, J.H.; Jahrling, P.B.; et al. Ebola virus genome plasticity as a marker of its passaging history: A comparison of in vitro passaging to non-human primate infection. PLoS One 2012, 7, e50316. [CrossRef] [PubMed].
6. Volchkov, V.E.; Chepurnov, A.A.; Volchkova, V.A.; Ternovoj, V.A.; Klenk, H.D. Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology 2000, 277, 147-155. [CrossRef] [PubMed].
7. Alfson, K.J.; Avena, L.E.; Beadles, M.W.; Menzie, H.; Patterson, J.L.; Carrion, R., Jr.; Griffiths, A. Genetic changes at the glycoprotein editing site associated with serial passage of Sudan virus. J. Infect. Dis. 2015, 212, S295-S304. [CrossRef] [PubMed].
8. World Health Organization. Ebola Situation Report-22 April 2015. Available online: http://apps.who.int/ebola/current-situation/ebola-situation-report-22-april-2015-0 (accessed on 18 December 2015).
9. Geisbert, T.W. Medical research: Ebola therapy protects severely ill monkeys. Nature 2014, 514, 41-43. [CrossRef] [PubMed].
10. Kraft, C.S.; Hewlett, A.L.; Koepsell, S.;Winkler, A.M.; Kratochvil, C.J.; Larson, L.; Varkey, J.B.; Mehta, A.K.; Lyon, G.M., 3rd; Friedman-Moraco, R.J.; et al. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin. Infect. Dis. 2015, 61, 496-502. [CrossRef] [PubMed].
11. Thi, E.P.; Mire, C.E.; Lee, A.C.; Geisbert, J.B.; Zhou, J.Z.; Agans, K.N.; Snead, N.M.; Deer, D.J.; Barnard, T.R.; Fenton, K.A.; et al. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature 2015, 521, 362-365. [CrossRef] [PubMed].
12. Agnandji, S.T.; Huttner, A.; Zinser, M.E.; Njuguna, P.; Dahlke, C.; Fernandes, J.F.; Yerly, S.; Dayer, J.A.; Kraehling, V.; Kasonta, R.; et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe-Preliminary report. N. Engl. J. Med. 2015. [CrossRef] [PubMed].
13. Mire, C.E.; Matassov, D.; Geisbert, J.B.; Latham, T.E.; Agans, K.N.; Xu, R.; Ota-Setlik, A.; Egan, M.A.; Fenton, K.A.; Clarke, D.K.; Eldridge, J.H.; et al. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature 2015, 520, 688-691. [CrossRef] [PubMed].
14. Regules, J.A.; Beigel, J.H.; Paolino, K.M.; Voell, J.; Castellano, A.R.; Muñoz, P.; Moon, J.E.; Ruck, R.C.; Bennett, J.W.; Twomey, P.S.; et al. A recombinant vesicular stomatitis virus Ebola vaccine-Preliminary report. N. Engl. J. Med. 2015. [CrossRef] [PubMed].
15. Lai, L.; Davey, R.; Beck, A.; Xu, Y.; Suffredini, A.F.; Palmore, T.; Kabbani, S.; Rogers, S.; Kobinger, G.; Alimonti, J.; et al. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. JAMA 2015, 313, 1249-1255. [CrossRef] [PubMed].
16. Warren, T.K.; Whitehouse, C.A.; Wells, J.; Welch, L.; Heald, A.E.; Charleston, J.S.; Sazani, P.; Reid, S.P.; Iversen, P.L.; Bavari, S. A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal Ebola virus infection. MBio 2015. [CrossRef] [PubMed].
17. Sarwar, U.N.; Costner, P.; Enama, M.E.; Berkowitz, N.; Hu, Z.; Hendel, C.S.; Sitar, S.; Plummer, S.; Mulangu, S.; Bailer, R.T.; et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J. Infect. Dis. 2015, 211, 549-557. [CrossRef] [PubMed].
18. Stanley, D.A.; Honko, A.N.; Asiedu, C.; Trefry, J.C.; Lau-Kilby, A.W.; Johnson, J.C.; Hensley, L.; Ammendola, V.; Abbate, A.; Grazioli, F.; et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against Ebola virus challenge. Nat. Med. 2014, 20, 1126-1129. [PubMed].
19. Mire, C.E.; Geisbert, J.B.; Agans, K.N.; Satterfield, B.A.; Versteeg, K.M.; Fritz, E.A.; Feldmann, H.; Hensley, L.E.; Geisbert, T.W. Durability of a vesicular stomatitis virus-based Marburg virus vaccine in nonhuman primates. PLoS One 2014, 9, e94355. [CrossRef] [PubMed].
20. Warren, T.K.; Wells, J.; Panchal, R.G.; Stuthman, K.S.; Garza, N.L.; van Tongeren, S.A.; Dong, L.; Retterer, C.J.; Eaton, B.P.; Pegoraro, G.; et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014, 508, 402-405. [CrossRef] [PubMed].
21. Qiu, X.; Wong, G.; Audet, J.; Bello, A.; Fernando, L.; Alimonti, J.B.; Fausther-Bovendo, H.; Wei, H.; Aviles, J.; Hiatt, E.; et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014, 514, 47-53. [CrossRef] [PubMed].
22. Rampling, T.; Ewer, K.; Bowyer, G.; Wright, D.; Imoukhuede, E.B.; Payne, R.; Hartnell, F.; Gibani, M.; Bliss, C.; Minhinnick, A.; et al. A monovalent chimpanzee adenovirus Ebola vaccine-Preliminary report. N. Engl. J. Med. 2015. [CrossRef] [PubMed].
23. Food and Drug Administration. Guidance for Industry Product Development Under the Animal Rule. May 2014. Available online: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm399217.pdf (accessed on 28 April 2015).
24. Safronetz, D.; Geisbert, T.W.; Feldmann, H. Animal models for highly pathogenic emerging viruses. Curr. Opin. Virol. 2013, 3, 205-209. [CrossRef] [PubMed].
25. Dye, J.M.; Herbert, A.S.; Kuehne, A.I.; Barth, J.F.; Muhammad, M.A.; Zak, S.E.; Ortiz, R.A.; Prugar, L.I.; Pratt, W.D. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Natl. Acad. Sci. USA 2012, 109, 5034-5039. [CrossRef] [PubMed].
26. Feldmann, H.; Jones, S.M.; Daddario-DiCaprio, K.M.; Geisbert, J.B.; Stroher, U.; Grolla, A.; Bray, M.; Fritz, E.A.; Fernando, L.; Feldmann, F.; et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog. 2007, 3, e2. [CrossRef] [PubMed].
27. Geisbert, T.W.; Hensley, L.E.; Jahrling, P.B.; Larsen, T.; Geisbert, J.B.; Paragas, J.; Young, H.A.; Fredeking, T.M.; Rote, W.E.; Vlasuk, G.P. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: A study in rhesus monkeys. Lancet 2003, 362, 1953-1958. [CrossRef].
28. Geisbert, T.W.; Lee, A.C.; Robbins, M.; Geisbert, J.B.; Honko, A.N.; Sood, V.; Johnson, J.C.; de Jong, S.; Tavakoli, I.; Judge, A.; et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study. Lancet 2010, 375, 1896-1905. [CrossRef].
29. Hensley, L.E.; Stevens, E.L.; Yan, S.B.; Geisbert, J.B.; Macias, W.L.; Larsen, T.; Daddario-DiCaprio, K.M.; Cassell, G.H.; Jahrling, P.B.; Geisbert, T.W. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J. Infect. Dis. 2007, 196, S390-S399. [CrossRef] [PubMed].
30. Marzi, A.; Yoshida, R.; Miyamoto, H.; Ishijima, M.; Suzuki, Y.; Higuchi, M.; Matsuyama, Y.; Igarashi, M.; Nakayama, E.; Kuroda, M.; et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One 2012, 7, e36192. [CrossRef] [PubMed].
31. Pratt, W.D.; Wang, D.; Nichols, D.K.; Luo, M.; Woraratanadharm, J.; Dye, J.M.; Holman, D.H.; Dong, J.Y. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin. Vaccine Immunol. 2010, 17, 572-581. [CrossRef] [PubMed].
32. Smith, L.M.; Hensley, L.E.; Geisbert, T.W.; Johnson, J.; Stossel, A.; Honko, A.; Yen, J.Y.; Geisbert, J.; Paragas, J.; Fritz, E.; et al. Interferon-beta therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J. Infect. Dis. 2013, 208, 310-318. [CrossRef] [PubMed].
33. Warren, T.K.; Warfield, K.L.; Wells, J.; Swenson, D.L.; Donner, K.S.; van Tongeren, S.A.; Garza, N.L.; Dong, L.; Mourich, D.V.; Crumley, S.; et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat. Med. 2010, 16, 991-994. [CrossRef] [PubMed].
34. Geisbert, T.W.; Daddario-Dicaprio, K.M.; Geisbert, J.B.; Reed, D.S.; Feldmann, F.; Grolla, A.; Ströher, U.; Fritz, E.A.; Hensley, L.E.; Jones, S.M.; et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 2008, 26, 6894-6900. [CrossRef] [PubMed].
35. Geisbert, T.W.; Geisbert, J.B.; Leung, A.; Daddario-DiCaprio, K.M.; Hensley, L.E.; Grolla, A.; Feldmann, H. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J. Virol. 2009, 83, 7296-7304. [CrossRef] [PubMed].
36. Jones, S.M.; Feldmann, H.; Stroher, U.; Geisbert, J.B.; Fernando, L.; Grolla, A.; Klenk, H.D.; Sullivan, N.J.; Volchkov, V.E.; Fritz, E.A.; et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 2005, 11, 786-790. [CrossRef] [PubMed].
37. Sullivan, N.J.; Geisbert, T.W.; Geisbert, J.B.; Xu, L.; Yang, Z.Y.; Roederer, M.; Koup, R.A.; Jahrling, P.B.; Nabel, G.J. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003, 424, 681-684. [CrossRef] [PubMed].
38. Geisbert, T.W.; Pushko, P.; Anderson, K.; Smith, J.; Davis, K.J.; Jahrling, P.B. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 2002, 8, 503-507. [CrossRef] [PubMed].
39. Shurtleff, A.C.; Biggins, J.E.; Keeney, A.E.; Zumbrun, E.E.; Bloomfield, H.A.; Kuehne, A.; Audet, J.L.; Alfson, K.J.; Griffiths, A.; Olinger, G.G.; et al. Standardization of the filovirus plaque assay for use in preclinical studies. Viruses 2012, 4, 3511-3530. [CrossRef] [PubMed].
40. Alfson, K.J.; Avena, L.E.; Beadles, M.W.; Staples, H.; Nunneley, J.W.; Ticer, A.; Dick, E.J., Jr.; Owston, M.A.; Reed, C.; Patterson, J.L.; et al. Particle-to-PFU ratio of Ebola virus influences disease course and survival in cynomolgus macaques. J. Virol. 2015, 89, 6773-6781. [CrossRef] [PubMed].
41. Warren, T.K.; Trefry, J.C.; Marko, S.T.; Chance, T.B.; Wells, J.B.; Pratt, W.D.; Johnson, J.C.; Mucker, E.M.; Norris, S.L.; Chappell, M.; et al. Euthanasia assessment in Ebola virus infected nonhuman primates. Viruses 2014, 6, 4666-4682. [CrossRef] [PubMed].
42. Shurtleff, A.C.; Warren, T.K.; Bavari, S. Nonhuman primates as models for the discovery and development of Ebola virus therapeutics. Expert. Opin. Drug Discov. 2011, 6, 233-250. [CrossRef] [PubMed].
43. Cooper, B.S.; Boni, M.F.; Pan-Ngum, W.; Day, N.P.; Horby, P.W.; Olliaro, P.; Lang, T.; White, N.J.; White, L.J.; Whitehead, J. Evaluating clinical trial designs for investigational treatments of Ebola virus disease. PLoS Med. 2015, 12, e1001815. [CrossRef] [PubMed].
44. Cooper, C.L.; Bavari, S. A race for an Ebola vaccine: Promises and obstacles. Trends Microbiol. 2015, 23, 65-66. [CrossRef] [PubMed].
45. Volchkova, V.A.; Dolnik, O.; Martinez, M.J.; Reynard, O.; Volchkov, V.E. Genomic RNA editing and its impact on Ebola virus adaptation during serial passages in cell culture and infection of guinea pigs. J. Infect. Dis. 2011, 204, S941-S946. [CrossRef] [PubMed].
46. Volchkov, V.E.; Volchkova, V.A.; Muhlberger, E.; Kolesnikova, L.V.; Weik, M.; Dolnik, O.; Klenk, H.D. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 2001, 291, 1965-1969. [CrossRef] [PubMed].
47. Martinez, O.; Leung, L.W.; Basler, C.F. The role of antigen-presenting cells in filoviral hemorrhagic fever: Gaps in current knowledge. Antiviral Res. 2012, 93, 416-428. [CrossRef] [PubMed].
48. Bray, M.; Geisbert, T.W. Ebola virus: The role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int. J. Biochem. Cell. Biol. 2005, 37, 1560-1566. [CrossRef] [PubMed].
49. Escudero-Perez, B.; Volchkova, V.A.; Dolnik, O.; Lawrence, P.; Volchkov, V.E. Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog. 2014, 10, e1004509. [CrossRef] [PubMed].
50. Rubins, K.H.; Hensley, L.E.;Wahl-Jensen, V.; Daddario DiCaprio, K.M.; Young, H.A.; Reed, D.S.; Jahrling, P.B.; Brown, P.O.; Relman, D.A.; Geisbert, T.W. The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. Genome Biol. 2007, 8. [CrossRef] [PubMed].
51. Volchkova, V.A.; Dolnik, O.; Martinez, M.J.; Reynard, O.; Volchkov, V.E. RNA editing of the GP gene of Ebola virus is an important pathogenicity factor. J. Infect. Dis. 2015. [CrossRef] [PubMed].
52. Bente, D.; Gren, J.; Strong, J.E.; Feldmann, H. Disease modeling for Ebola and Marburg viruses. Dis. Model Mech. 2009, 2, 12-17. [CrossRef] [PubMed].
53. Martines, R.B.; Ng, D.L.; Greer, P.W.; Rollin, P.E.; Zaki, S.R. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J. Pathol. 2015, 235, 153-174. [CrossRef] [PubMed].
54. Hoenen, T.; Marzi, A.; Scott, D.P.; Feldmann, F.; Callison, J.; Safronetz, D.; Ebihara, H.; Feldmann, H. Soluble glycoprotein is not required for Ebola virus virulence in Guinea pigs. J. Infect. Dis. 2015. [CrossRef] [PubMed].
55. Tsuda, Y.; Hoenen, T.; Banadyga, L.; Weisend, C.; Ricklefs, S.M.; Porcella, S.F.; Ebihara, H. An improved reverse genetics system to overcome cell-type-dependent Ebola virus genome plasticity. J. Infect. Dis. 2015. [CrossRef] [PubMed].